SCHEMBL3263412

SCHEMBL3263412

CCCCCC1CC(=O)N(CC(=O)OCC)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.40
POLB P06746 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
FKBP1A P62942 2/20 0.38
FKBP4 Q02790 1/20 0.38
FKBP5 Q13451 1/20 0.38
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
ELANE P08246 1/20 0.36
CYP1A2 P05177 1/20 0.36
ABL1 P00519 1/20 0.35
RIN1 Q13671 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
MEN1 O00255 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
ALOX15 P16050 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NAAA Q02083 1/20 0.35
BRD4 O60885 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3263411 1.00 ALDH1A1 (0.40) ALDH1A1POLBL3MBTL1FKBP1AFKBP4
SCHEMBL6949518 0.90 GSK3A (0.41) ALDH1A1FKBP1AFKBP4FKBP5GSK3A
SCHEMBL563087 0.82 GSK3A (0.41) ALDH1A1FKBP1AFKBP4FKBP5GSK3A
SCHEMBL563088 0.82 GSK3A (0.41) ALDH1A1FKBP1AFKBP4FKBP5GSK3A
SCHEMBL563774 0.82 APEX1 (0.54) L3MBTL1FKBP1ACYP1A2MEN1KMT2A
SCHEMBL9203370 0.77 APEX1 (0.58) ALDH1A1FKBP1AFKBP4FKBP5GSK3A
SCHEMBL9203374 0.77 APEX1 (0.58) ALDH1A1FKBP1AFKBP4FKBP5GSK3A
SCHEMBL9301450 0.77 APEX1 (0.58) ALDH1A1FKBP1AFKBP4FKBP5GSK3A
SCHEMBL9301677 0.74 GSK3A (0.41) ALDH1A1FKBP1AFKBP4FKBP5GSK3A
SCHEMBL10681074 0.74 ALDH1A1 (0.43) ALDH1A1POLBL3MBTL1GSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9102615-B2 N-Carbamoylmethy1-4-(R)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use Joint Stock Company (JSC) “OLAINFARM” (LV) 2015-08-11 US claimed
EP-2013166-B1 N-CARBAMOYLMETHYL-4(R)-PHENYL-2-PYRROLIDINONE, METHOD OF ITS PREPARATION AND PHARMACEUTICAL USE AKCIJU SABIEDRIBA OLAINFARM (LV) 2010-03-10 EP claimed
US-20100022784-A1 N-Carbamoylmethyl-4-(R)-Phenyl-2-Pyrrolidinone, Method of its Preparation and Pharmaceutical Use Joint Stock Company "Olainfarm" (LV) 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022784-A1 N-Carbamoylmethyl-4-(R)-Phenyl-2-Pyrrolidinone, Method of its Preparation and Pharmaceutical Use PRMT6, CPS1, JMJD6 ALDH1A1 3160/4885POLB 1370/4885L3MBTL1 4683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.